Wolverine Trading’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,120
| Closed | -$228K | – | 5562 |
|
|
2025
Q1 | $244K | Sell |
6,120
-34,627
| -85% | -$1.17M | ﹤0.01% | 3747 |
|
|
2024
Q4 | $1.28M | Buy |
40,747
+28,468
| +232% | +$817K | ﹤0.01% | 2409 |
|
|
2024
Q3 | $293K | Sell |
12,279
-2,483
| -17% | -$54.2K | ﹤0.01% | 3657 |
|
|
2024
Q2 | $263K | Sell |
14,762
-29,478
| -67% | -$470K | ﹤0.01% | 3542 |
|
|
2024
Q1 | $673K | Buy |
+44,240
| New | +$705K | ﹤0.01% | 2571 |
|
|
2023
Q4 | – | Sell |
-24,155
| Closed | -$281K | – | 5215 |
|
|
2023
Q3 | $202K | Sell |
24,155
-3,744
| -13% | -$52.2K | ﹤0.01% | 3740 |
|
|
2023
Q2 | $673K | Buy |
+27,899
| New | +$721K | ﹤0.01% | 2342 |
|
|
2022
Q2 | – | Sell |
-13,720
| Closed | -$85.7K | – | 5715 |
|
|
2022
Q1 | $135K | Sell |
13,720
-10,008
| -42% | -$116K | ﹤0.01% | 4674 |
|
|
2021
Q4 | $459K | Sell |
23,728
-606
| -2% | -$15.7K | ﹤0.01% | 3575 |
|
|
2021
Q3 | $817K | Sell |
24,334
-5,725
| -19% | -$177K | ﹤0.01% | 3270 |
|
|
2021
Q2 | $1.13M | Buy |
30,059
+760
| +3% | +$29.8K | ﹤0.01% | 2617 |
|
|
2021
Q1 | $1.33M | Sell |
29,299
-56,930
| -66% | -$2.74M | ﹤0.01% | 2393 |
|
|
2020
Q4 | $4.56M | Sell |
86,229
-8,573
| -9% | -$290K | 0.01% | 1121 |
|
|
2020
Q3 | $2.48M | Buy |
94,802
+14,387
| +18% | +$331K | 0.01% | 1319 |
|
|
2020
Q2 | $1.49M | Sell |
80,415
-23,003
| -22% | -$370K | ﹤0.01% | 1628 |
|
|
2020
Q1 | $1.07M | Buy |
103,418
+942
| +0.9% | +$11.9K | ﹤0.01% | 1865 |
|
|
2019
Q4 | $1.11M | Buy |
102,476
+2,619
| +3% | +$19.9K | ﹤0.01% | 2312 |
|
|
2019
Q3 | $564K | Buy |
99,857
+19,764
| +25% | +$138K | ﹤0.01% | 2510 |
|
|
2019
Q2 | $693K | Sell |
80,093
-61,208
| -43% | -$463K | ﹤0.01% | 2382 |
|
|
2019
Q1 | $1.14M | Buy |
141,301
+68,171
| +93% | +$368K | ﹤0.01% | 1955 |
|
|
2018
Q4 | $291K | Buy |
73,130
+25,295
| +53% | +$126K | ﹤0.01% | 3235 |
|
|
2018
Q3 | $268K | Buy |
47,835
+29,009
| +154% | +$331K | ﹤0.01% | 3883 |
|
|
2018
Q2 | $267K | Hold |
18,826
| – | – | ﹤0.01% | 3953 |
|
|
2018
Q1 | $267K | Buy |
+18,826
| New | +$241K | ﹤0.01% | 3953 |
|
|
2017
Q3 | – | Sell |
-45,150
| Closed | -$514K | – | 5026 |
|
|
2017
Q2 | $479K | Buy |
+45,150
| New | +$505K | ﹤0.01% | 2477 |
|
|
2017
Q1 | – | Sell |
-12,090
| Closed | -$86.8K | – | 4975 |
|
|
2016
Q4 | $56K | Buy |
+12,090
| New | +$70.9K | ﹤0.01% | 4189 |
|
|
2016
Q3 | – | Sell |
-12,055
| Closed | -$72K | – | 5104 |
|
|
2016
Q2 | $72K | Buy |
+12,055
| New | +$98K | ﹤0.01% | 3734 |
|
Other funds holding TGTX
SCM
HRCM
Wolverine Trading's TGTX Position: Q2 2025 in Review
Wolverine Trading sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 6,120 shares — an estimated $228K sold.
Wolverine Trading first reported a position in TGTX in Q2 2016 and held it in 27 quarters. The position peaked at $4.56M in Q4 2020. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.
- Wolverine Trading reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
- Wolverine Trading sold 6,120 TG Therapeutics shares in Q2 2025, an estimated $228K.
- Wolverine Trading first reported a position in TG Therapeutics in Q2 2016 and held it in 27 quarters.
- Wolverine Trading's TG Therapeutics position peaked at $4.56M in Q4 2020.
- 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.
Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.